Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Recipharm Acquires Sanofi’s UK CMO Biz | Contract Pharma
Breaking News

Recipharm Acquires Sanofi’s UK CMO Biz

Expands inhalation capabilities with commercial drug product manufacturing

Recipharm has acquired Sanofi’s manufacturing center and business in Holmes Chapel, UK, expanding its inhalation capabilities in the growing respiratory drug market with commercial drug product manufacturing. Recipharm also has an inhalation development facility in the U.S.

The Holmes Chapel manufacturing facility is located close to Manchester and serves several clients from the facility and a number of products. The site manufactures flutiform for Vectura Group plc. As part of the transaction, Sanofi has entered into a long-term supply agreement for the products currently manufactured at the facility.

The technologies at Holmes Chapel include metered dose inhalers and nasal sprays. The facility also houses development areas for dry powder inhalation technologies.The site covers 125,000 m2 and employs a team of more than 450 specialist employees.

Thomas Eldered, chief executive officer of Recipharm, said, “Holmes Chapel brings Recipharm an ideal opportunity to accelerate its offering to customers with access to novel of respiratory products. As an already successful CMO with several clients, we look forward to introducing new contracts to Holmes Chapel by utilizing our growing franchise in development services. Treatments for asthma and chronic obstructive pulmonary disease (COPD) are growing at a fast rate and we see many opportunities. The experienced management team and staff have already successfully attracted new customers and we look forward to building on this from the well invested facility.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters